# KO61936

# 510(K) SUMMARY

In accordance with 21 CFR 807.92

#### 1. Date of preparation

June 28, 2006

# 2. Company information

AUG 1 8 2006

BarcoView
35 President Kennedypark
B-8500 Kortrijk, Belgium
Tel. +32-(0)56-233-211
Fax +32-(0)56-233-457

# 3. Contact person

Lieven De Wandel
Official correspondent

#### 4. Device information

Trade name: Coronis 2MP

Common name: Display system, medical image workstation, and others

Classification name: System, Image Processing

Classification number: 21 CFR 892.2050 / Procode 90LLZ

#### 5. Predicate device

Name: Coronis 2MP-21"
510(k) number: K052403
Manufacturer: Barco NV

#### 6. Device description

Coronis 2MP is a display system for medical viewing. It consists of 3 components:

MDCG 2121-CB is a 21.3" grayscale LCD display. BarcoMed Coronis PCIe is a fast high-resolution display controller board that plugs into a PACS workstation computer. MediCal QAWeb Agent is a softcopy QA software application for local calibration and QA control.

The display system can be a single-head system or multi-head system. In the last case it nations multiple displays and display controller boards.

# 7. Intended use

"The Coronis 2MP is intended to be used in displaying and viewing digital images for review by trained medical practitioners. These devices must not be used in primary image diagnosis in mammography.

# 8. Summary of technological characteristics

The device consists of three components:

- One 2-megapixel flat panel display (MDCG 2121-CB)
- One 10-bit display controller (BarcoMed Coronis PCIe board)
- MediCal QAWeb Agent software

The flat panel display has a resolution of 1600x1200 pixels. It can be used in landscape and portrait mode.

The BarcoMed Coronis PCIe display controller board is an ultra-high speed board with a 10-bit in, 10-bit out lookup table, providing 256 simultaneous shades of gray.

The MediCal QAWeb Agent software allows to set the display function, display test patterns, calibrate the display and view additional display and display controller information.

Compared to the predicate device, the display from the Coronis 2MP system has a different LCD panel, other electronic boards and other mechanical parts. The software is a new version. However, the basic specifications and functions of all the parts are the same.

The device does not come into contact with the patient. It does not control any life sustaining devices either.

#### 9. Conclusion:

The Barco Coronis 2MP is substantially equivalent to the predicate device, Coronis 2MP-21". The new and predicate devices are substantially equivalent in the areas of technical characteristics, general function, application and intended use.

Any difference between both devices does not affect safety or efficacy.

The 510(k) Pre-Market Notification for the Barco Coronis 2MP contains adequate information and data to enable FDA – CDRH to determine substantial equivalence to the predicate device.

#### **DEPARTMENT OF HEALTH & HUMAN SERVICES**



Food and Drug Administration 9200 Corporate Blvd. Rockville MD 20850

# AUG 1 8 2006

Mr. Lieven De Wandel Official Correspondent Barco-Medical Imaging Systems President Kennedypark 35, B-8500 Kortrijk BELGIUM

Re: K061926

Trade/Device Name: MDCG-2121-CB Regulation Number: 21 CFR 892.2050

Regulation Name: Picture archiving and communications system

Regulatory Class: II Product Code: LLZ Dated: June 28, 2006 Received: July 7, 2006

### Dear Mr. De Wandel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.



Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxx	(Gastroenterology/Renal/Urology	240-276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 894.xxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Mancy Cbroadon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

# **INDICATIONS FOR USE**

510(k) Number (if known):
Device Name: MDCG 2121-CB
Indications for Use: The MDCG 2121-CB is intended to be used in displaying and viewing digital images for review by trained medical practitioners. These devices must not be used in primary image diagnosis i mammography.
Prescription UseXX  (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use  (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Reproductive, Abdominal, and Radiological Devices KO61926
510(k) Number